China Resources Pharmaceutical Group Dirección
Dirección controles de criterios 3/4
China Resources Pharmaceutical Group's El consejero delegado es Xiaosong Bai , nombrado en Jan 2022, tiene un mandato de 2.08 años. la remuneración anual total es HK$2.89M , compuesta por 98% salario y 2% primas, incluidas acciones y opciones de la empresa. posee directamente 0.003% de las acciones de la empresa, por valor de HK$950.97K . La antigüedad media del equipo directivo y del consejo de administración es de 2.3 años y 3.6 años respectivamente.
Información clave
Xiaosong Bai
Chief Executive Officer (CEO)
CN¥2.6m
Compensación total
| Porcentaje del salario del CEO | 98.0% |
| Permanencia del CEO | 2.3yrs |
| Participación del CEO | 0.003% |
| Permanencia media de la dirección | 2.4yrs |
| Promedio de permanencia en la Junta Directiva | 3.8yrs |
Actualizaciones recientes de la dirección
Recent updates
China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To CN¥0.1697
Apr 14
China Resources Pharmaceutical Group's (HKG:3320) Dividend Will Be Increased To CN¥0.1697
Mar 28China Resources Pharmaceutical Group Limited's (HKG:3320) Shares May Have Run Too Fast Too Soon
Jan 28We Think China Resources Pharmaceutical Group (HKG:3320) Is Taking Some Risk With Its Debt
Dec 06Does China Resources Pharmaceutical Group (HKG:3320) Have A Healthy Balance Sheet?
Sep 07Does This Valuation Of China Resources Pharmaceutical Group Limited (HKG:3320) Imply Investors Are Overpaying?
Aug 02With EPS Growth And More, China Resources Pharmaceutical Group (HKG:3320) Makes An Interesting Case
May 26These 4 Measures Indicate That China Resources Pharmaceutical Group (HKG:3320) Is Using Debt Reasonably Well
May 05China Resources Pharmaceutical Group's (HKG:3320) Shareholders Will Receive A Bigger Dividend Than Last Year
Apr 04Is There An Opportunity With China Resources Pharmaceutical Group Limited's (HKG:3320) 24% Undervaluation?
Jan 24Is China Resources Pharmaceutical Group (HKG:3320) Using Too Much Debt?
Dec 15China Resources Pharmaceutical Group Limited's (HKG:3320) Intrinsic Value Is Potentially 97% Above Its Share Price
Oct 18China Resources Pharmaceutical Group (HKG:3320) Takes On Some Risk With Its Use Of Debt
Aug 27China Resources Pharmaceutical Group (HKG:3320) Has Announced That It Will Be Increasing Its Dividend To HK$0.15
May 29China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To HK$0.15
May 02China Resources Pharmaceutical Group's (HKG:3320) Upcoming Dividend Will Be Larger Than Last Year's
Apr 07China Resources Pharmaceutical Group (HKG:3320) Has A Somewhat Strained Balance Sheet
Mar 31Are Investors Undervaluing China Resources Pharmaceutical Group Limited (HKG:3320) By 23%?
Feb 21Here's Why China Resources Pharmaceutical Group (HKG:3320) Can Manage Its Debt Responsibly
Dec 07China Resources Pharmaceutical Group Limited (HKG:3320) Shares Could Be 32% Below Their Intrinsic Value Estimate
Nov 10These 4 Measures Indicate That China Resources Pharmaceutical Group (HKG:3320) Is Using Debt Reasonably Well
Aug 29Is China Resources Pharmaceutical Group Limited (HKG:3320) Trading At A 21% Discount?
Aug 03Is China Resources Pharmaceutical Group Limited (HKG:3320) A Good Fit For Your Dividend Portfolio?
May 03Is China Resources Pharmaceutical Group (HKG:3320) A Risky Investment?
Apr 12Is China Resources Pharmaceutical Group Limited's (HKG:3320) Recent Stock Performance Influenced By Its Fundamentals In Any Way?
Mar 17An Intrinsic Calculation For China Resources Pharmaceutical Group Limited (HKG:3320) Suggests It's 24% Undervalued
Feb 14If You Had Bought China Resources Pharmaceutical Group's (HKG:3320) Shares Three Years Ago You Would Be Down 63%
Jan 17
We Think China Resources Pharmaceutical Group (HKG:3320) Is Taking Some Risk With Its Debt
Nov 29Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | CN¥4b |
| Jun 30 2023 | n/a | n/a | CN¥4b |
| Mar 31 2023 | n/a | n/a | CN¥4b |
| Dec 31 2022 | CN¥3m | CN¥2m | CN¥4b |
Compensación vs. Mercado: Xiaosong($USD369.70K) está por debajo de la media de empresas de tamaño similar en el mercado Hong Kong ($USD717.30K).
Compensación vs. Ingresos: Datos insuficientes para comparar la remuneración de Xiaosong con los resultados de la empresa.
CEO
Xiaosong Bai (52 yo)
2.3yrs
Permanencia
CN¥2,550,953
Compensación
Mr. Xiaosong Bai serves as Non-Independent Director of China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. since March 3, 2022. He serves as Executive Director and Chief Executive Officer at China Re...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO & Executive Director | 2.3yrs | CN¥2.55m | 0.0032% CN¥ 951.0k | |
| VP & Executive Director | 2.6yrs | CN¥2.76m | sin datos | |
| CFO & Executive Director | less than a year | sin datos | sin datos | |
| Chief Information Officer & VP | 10.3yrs | sin datos | sin datos | |
| Chief Legal Advisor | 10.1yrs | sin datos | sin datos | |
| Company Secretary | less than a year | sin datos | sin datos | |
| Vice President | no data | sin datos | sin datos | |
| Vice President of CR Pharma & Chairman of China Resources Boya | no data | sin datos | sin datos |
2.4yrs
Permanencia media
51yo
Promedio de edad
Equipo directivo experimentado: 3320El equipo directivo de la empresa se considera experimentado (2.1 años de antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO & Executive Director | 2.3yrs | CN¥2.55m | 0.0032% CN¥ 951.0k | |
| VP & Executive Director | 2.6yrs | CN¥2.76m | sin datos | |
| CFO & Executive Director | less than a year | sin datos | sin datos | |
| Independent Non-Executive Director | 7.8yrs | CN¥265.08k | sin datos | |
| Non-Executive Director | 2.3yrs | sin datos | sin datos | |
| Independent Non-Executive Director | 7.8yrs | CN¥265.08k | sin datos | |
| Independent Non-Executive Director | 7.8yrs | CN¥265.08k | sin datos | |
| Chairman of China Resources Double-Crane Pharmaceutical Co. | 5.3yrs | sin datos | sin datos | |
| Non-Executive Director | 1.2yrs | sin datos | sin datos | |
| Independent Non-Executive Director | 6.7yrs | CN¥265.08k | sin datos | |
| Chairman | 4.5yrs | CN¥2.62m | 0.0048% CN¥ 1.4m | |
| Non-Executive Director | 3.1yrs | sin datos | sin datos |
3.8yrs
Permanencia media
57.5yo
Promedio de edad
Junta con experiencia: La junta directiva de 3320 se considera experimentada (3.5 años de antigüedad promedio).